A127120 Stock Overview
DNA Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
DNA Link, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,900.00 |
| 52 Week High | ₩4,450.00 |
| 52 Week Low | ₩2,315.00 |
| Beta | 0.26 |
| 1 Month Change | -0.68% |
| 3 Month Change | -8.95% |
| 1 Year Change | -8.81% |
| 3 Year Change | -41.65% |
| 5 Year Change | -27.41% |
| Change since IPO | -83.62% |
Recent News & Updates
Shareholder Returns
| A127120 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 17.4% | 1.1% | -0.4% |
| 1Y | -8.8% | 9.1% | 6.0% |
Return vs Industry: A127120 underperformed the KR Biotechs industry which returned 9.1% over the past year.
Return vs Market: A127120 underperformed the KR Market which returned 6% over the past year.
Price Volatility
| A127120 volatility | |
|---|---|
| A127120 Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A127120 has not had significant price volatility in the past 3 months.
Volatility Over Time: A127120's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 80 | Jong-Eun Lee | dnalink.com |
DNA Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay.
DNA Link, Inc. Fundamentals Summary
| A127120 fundamental statistics | |
|---|---|
| Market cap | ₩54.19b |
| Earnings (TTM) | -₩5.60b |
| Revenue (TTM) | ₩21.95b |
2.5x
P/S Ratio-9.7x
P/E RatioIs A127120 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A127120 income statement (TTM) | |
|---|---|
| Revenue | ₩21.95b |
| Cost of Revenue | ₩16.48b |
| Gross Profit | ₩5.47b |
| Other Expenses | ₩11.07b |
| Earnings | -₩5.60b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -299.46 |
| Gross Margin | 24.92% |
| Net Profit Margin | -25.50% |
| Debt/Equity Ratio | 12.9% |
How did A127120 perform over the long term?
See historical performance and comparison